Advertisement - see our Ad Policy
Advertisement - see our Ad Policy

Eroxon® Topical Gel for Erectile Dysfunction


In June, 2023, the United States Food & Drug Administration (FDA) approved the over-the-counter sale of Eroxon® StimGel, a topical glyceryl trinitrate gel for the treatment of erectile dysfunction.

Eroxon is not a cure. Like oral drugs for erectile dysfunction (PDE5 inhibitors), Eroxon is used shortly before sex, and allows most men to achieve an erection.

Although a small study in 19991 showed no benefit from the transcutaneous application of glyceryl trinitrate, subsequent clinical trials2 3 have shown it to be an effective alternative to PDE5 inhibitors. It is faster acting (about 10 minutes, versus 30-60), and has fewer side effects. There are no known serious adverse reactions, and no known interactions with drug therapies.

Eroxon is not a drug. It is a formulation of glyceryl trinitrate (composed of water, ethanol, propylene glycol, glycerin, carbomer and potassium hydroxide). The gel is applied to the head of the penis and evaporates in seconds. This evaporative action produces a rapid cooling, followed by a gradual warming sensation, which stimulates nerve endings in the glans and increases blood flow to the corpus cavernosum.

While Eroxon seems like an attractive option, it is currently very expensive. A package with eight single-dose tubes is currently selling on for $95.99.

Related Reading


  1. Gramkow, J; Lendorf, A; Zhu, J; Meyhoff, H H. “Transcutaneous nitroglycerine in the treatment of erectile dysfunction: a placebo controlled clinical trial.” International Journal of Impotence Research. Feb 1999; 11(1):35-9.
  2. Ralph, David J; Eardley, Ian; Taubel, Jorg; Terrill, Paul; Holland, Tim. “Efficacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in the Treatment of Erectile Dysfunction: A Randomized Crossover Study.” The Journal of Sexual Medicine. February 2018;15(2):167-175. <>
  3. “Eroxon Clinical Trials.” Futura Medical.

Comments are closed.